Effekten af PERT til PEI ved uopsederbar bugspytkirtelkræft. (PERTseverance)
Open Label Randomized, Multicenter, Controlled Trial of Pancreatic Enzyme Replacement Therapy (PERT) for pancreatisk eksokrin insufficiens (PEI) hos patienter med ikke-operabel pancreascancer. PERT-fratrædelsessagen.
- This will a be an open label, multicentre, randomized, controlled study in patients with unresectable pancreatic cancer, locally advanced or metastatic, with significant weight loss, and the tumour located in the head of the pancreas associated with dilated main pancreatic duct. Pancreatic Exocrine Replacement Therapy (PERT) in these patients will be given on top of other required therapies (best standard of care, BSC), including oncologic therapies, diabetes mellitus therapies and acid suppressants and nutritional support as appropriate. The duration of the study will be up to six months.
Consecutive patients meeting inclusion criteria and none of the exclusion criteria will be evaluated for the study. Those patients signing the informed consent for study participation will be randomized to one of the following two arms:
- The experimental arm will receive the best standard of care (BSC) and PERT (capsules containing pancreatin 35,000 Ph.U.) at a fixed dose of 3 capsules with main meals (breakfast, lunch and dinner) and 2 capsules with snacks over 6 months.
- The control arm will receive the BSC over 3 months, followed by a further 3-month open uncontrolled phase of BSC + PERT at the dose mentioned above.
All patients will receive in addition a proton pump inhibitor (PPI) bid (any PPI at standard dose is acceptable -omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, rabeprazole 20 mg, esomeprazole 40 mg) while on PERT, 20-30 minutes before breakfast and dinner.
To make the two arms comparable, patients will be stratified in two groups (locally advanced and metastatic pancreatic cancer) for randomization using computer generated random numbers.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
- Navn: J. Enrique Dominguez-Munoz, PhD, MD
- Telefonnummer: +34981951364
- E-mail: juan.enrique.dominguez.munoz@sergas.es
Studiesteder
-
-
-
Milan, Italien, 20132
- Rekruttering
- Istituto di Ricovero e Cura Carattere Scientifico San Raffaele
-
Kontakt:
- MhD
- Telefonnummer: +39 06 660581
- E-mail: capurso.gabriele@hsr.it
-
-
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Spanien, 15706
- Rekruttering
- University Hospital of Santiago de Compostela
-
Kontakt:
- J. Enrique Dominguez-Munoz, PhD, MD
- Telefonnummer: +34981951364
- E-mail: juan.enrique.dominguez.munoz@sergas.es
-
-
Navarre
-
Pamplona, Navarre, Spanien, 31008
- Rekruttering
- Hospital Universitario de Navarra
-
Kontakt:
- MhD
- Telefonnummer: 848422222
- E-mail: federico.bolado.concejo@navarra.es
-
-
-
-
-
Stockholm, Sverige, 17177
- Ikke rekrutterer endnu
- Karolinska Institutet
-
Kontakt:
- MhD
- Telefonnummer: +46 8 524 800 00
- E-mail: matthias.lohr@ki.se
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Pathologically confirmed unresectable, locally advanced or metastatic, pancreatic cancer.
- Tumour located in the head of the pancreas.
- Dilated main pancreatic duct confirmed by imaging methods (CT scan, MRI and/or EUS).
- Significant weight loss (≥5% of the usual body weight) at screening.
- Life expectancy of at least six months at screening.
- Signed informed consent to the study.
Exclusion Criteria:
- Hypersensitivity to pancreatin of porcine origin or to any of the excipients.
- Patients on neoadjuvant therapy, or in whom neoadjuvant therapy is planned.
- Patients already on PERT.
- Prior history of upper gastrointestinal or pancreatic surgery.
- Short life expectancy (shorter than 6 months).
- Patients on second line or beyond chemotherapy (those who failed with first line chemotherapy therapy).
- Patients in whom a pancreatic stent has been placed.
- Unsolved gastric outlet obstruction.
- Unwillingness to participate in the study.
- Inability to comply with the study visits and study protocol, whatever the reason.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: experimental arm
Creon 35.000 Ph.U (R) at a fixed dose of 3 capsules orally with main meals (breakfast, lunch and dinner) and 2 capsules with snacks over 6 months post randomization. |
Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period. |
|
Andet: control arm
Creon 35.000 Ph.U (R) at a fixed dose of 3 capsules orally with main meals (breakfast, lunch and dinner) and 2 capsules with snacks during the last 3 months post randomization. |
Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in body weight over study period.
Tidsramme: From visit 1 day 1 to visit 4 sixt month.
|
ƍ between visit 4 (sixt month) and visit 1 (day 1) in the patient's weight |
From visit 1 day 1 to visit 4 sixt month.
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- PEI004/2021
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .